Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company that regularly issues news on its operations, strategy and pipeline across generics, established brands and innovative medicines. This news page aggregates company announcements, press releases and third-party coverage related to VTRS, giving readers a single place to review the latest corporate developments.
Viatris frequently reports on regulatory milestones in its global pipeline. Recent updates include FDA approval of octreotide acetate for injectable suspension as a generic version of Sandostatin LAR Depot, FDA acceptance of a New Drug Application for a low dose estrogen weekly contraceptive patch, FDA clearance of an IND for the MR‑146 gene therapy candidate in neurotrophic keratopathy, and acceptance of a Japanese New Drug Application for pitolisant in obstructive sleep apnea syndrome. The company also announces progress in Japan and the Asia-Pacific region, such as the acquisition of Aculys Pharma and rights to pitolisant and Spydia nasal spray.
Investors can also find financial and corporate news, including quarterly results, updates to financial guidance, capital return actions like dividends and share repurchases, and information on enterprise-wide strategic reviews. Viatris’ participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and other sector events, is typically announced through press releases that are reflected in the news flow.
Additional news items may cover business development and collaborations, such as research agreements to develop engineered bacteriophage products for ophthalmic infections, as well as governance updates, board appointments and changes to corporate bylaws. For anyone tracking VTRS, this page offers a concise view of how Viatris communicates its strategy to strengthen its core portfolio, expand innovative brands and optimize its global structure.
On December 1, 2021, Viatris (NASDAQ: VTRS) announced that the U.S. Court of Appeals affirmed a prior ruling that invalidated Biogen's Tecfidera patent for lack of written description. This decision supports Viatris' launch of a generic version of Tecfidera in August 2020, facilitating greater access to multiple sclerosis treatments. CEO Michael Goettler expressed satisfaction with the ruling, highlighting Viatris' commitment to improving patient access to affordable medications.
Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 7:30 a.m. ET. Executives Michael Goettler, Rajiv Malik, and Sanjeev Narula will engage in a discussion regarding company insights. Investors can access the live webcast at investor.viatris.com. An archived version will also be available post-event. Viatris aims to empower global healthcare access and provides over 1,400 approved molecules in diverse therapeutic areas.
Viatris (NASDAQ: VTRS) and Biocon Biologics announced the U.S. launch of interchangeable biosimilars SEMGLEE® (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn) to aid in controlling high blood sugar for diabetes patients. Both products are available in various forms and can be substituted for the reference brand LANTUS®. Viatris emphasizes their commitment to improving access to affordable healthcare through a range of patient assistance programs, including copay and cash-pay options, effective from 2022.
Viatris Inc. (NASDAQ: VTRS) announced a $1 million donation to SBP, focusing on the Got Your Back Fund, which supports low-to-moderate income U.S. veterans in disaster recovery. This partnership aims to address housing instability exacerbated by COVID-19 by providing rebuilt and modified homes for veterans with disabilities. Viatris has contributed over $3 million to SBP since 2016, reinforcing its commitment to social support. The CEO emphasized the importance of funding in disaster recovery, particularly for veterans, while SBP's CEO expressed gratitude for Viatris's support in easing access to assistance.
Pittsburgh, Nov. 8, 2021 - Viatris reported Q3 2021 financial results with total revenues of $4.54 billion, U.S. GAAP net earnings of $312 million, and adjusted EBITDA of $1.70 billion. The company raised its 2021 financial guidance, projecting total revenues between $17.70 billion and $17.90 billion. Free cash flow is now expected to range between $2.40 billion and $2.60 billion. Viatris returned $266 million to shareholders in dividends and reduced debt by $1.9 billion in the first three quarters. A virtual investor event is scheduled for January 7, 2022.
On October 20, 2021, Viatris Inc. (NASDAQ: VTRS) announced that its interchangeable biosimilar Semglee® (insulin glargine-yfgn) will be listed as a preferred insulin brand on Express Scripts' National Preferred Formulary, impacting over 28 million lives. This decision aims to enhance patient access to affordable insulin, with both Semglee and its authorized counterpart set to launch before year-end 2021. The formulary change will take effect on January 1, 2022, promoting greater adoption of insulin among patients with diabetes.
Viatris Inc. (NASDAQ: VTRS) will release its third quarter 2021 financial results on November 8 before the U.S. market opens. CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will host a webcast at 10 a.m. ET on the same day to discuss the results. Investors can access the live webcast via investor.viatris.com or by phone. Viatris, formed in November 2020, operates globally and has a portfolio of over 1,400 approved medicines.
Viatris Inc. (NASDAQ: VTRS) has been ranked fifth on Fortune's Change the World list, recognizing its positive societal impact through healthcare initiatives. The company was acknowledged for expanding access to HIV medications in low- and middle-income countries via public-private partnerships. Key achievements include introducing a low-cost dolutegravir regimen for $75 per year and a pediatric version at a 75% reduced cost, promoting affordable treatment. Viatris serves over 40% of global HIV patients and emphasizes its commitment to social responsibility and innovative healthcare solutions.
Viatris reported Q2 2021 revenues of $4.58 billion with a GAAP net loss of $279 million. Adjusted EBITDA stood at $1.68 billion, while net cash from operating activities was $559 million and free cash flow reached $470 million. The company raised its full-year guidance: total revenues are now expected to be between $17.5 billion and $17.9 billion, adjusted EBITDA between $6.15 billion and $6.45 billion, and free cash flow between $2.2 billion and $2.4 billion. Additionally, a quarterly dividend of $0.11 per share was declared, and $1.15 billion of debt was paid down in H1 2021.
Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. announced the FDA approval of Semglee® (insulin glargine-yfgn injection) as the first interchangeable biosimilar under the 351(k) pathway. This approval allows Semglee to be substituted for Lantus® at pharmacies and is expected to enhance access to diabetes treatment. The companies will launch Semglee by the end of the year and may enjoy 12 months of exclusivity before competing biosimilars can enter the market. This significant milestone reflects Viatris’ scientific capabilities and commitment to increasing patient access to complex treatments.